Quantitative assessment of myeloid nuclear differentiation antigen distinguishes myelodysplastic syndrome from normal bone marrow

American Journal of Clinical Pathology

Volumn 135, Issue 3, 2011, Pages 380-385

  McClintock Treep, Sara A ^a   Briggs, Robert C ^a   Shults, Keith E ^a,b   Flye Blakemore, Leanne A ^a   Mosse, Claudio A ^a,c   Jagasia, Madan H ^d   Shinar, Andrew A ^d   Dupont, William D ^d   Stelzer, Greg T ^a,b   Head, David R ^a,b  

^a Esoterix Center for Innovation   (United States)

^b Department of Nodality ^*  (United States)

^c Tennessee Valley Healthcare System   (United States)

^d VANDERBILT UNIVERSITY   (United States)

Author keywords

Diagnostic test; MDS; MNDA; Myelodysplastic syndrome; Myeloid nuclear differentiation antigen

Indexed keywords

DIFFERENTIATION ANTIGEN; MYELOID NUCLEAR DIFFERENTIATION ANTIGEN; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CELL POPULATION; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; MALE; MYELODYSPLASTIC SYNDROME; MYELOID PROGENITOR CELL; PRESCHOOL CHILD; PRIORITY JOURNAL; QUANTITATIVE DIAGNOSIS; BONE MARROW; BONE MARROW CELL; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY; PREDICTIVE VALUE; PROGNOSIS; RECEIVER OPERATING CHARACTERISTIC;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; BONE MARROW; BONE MARROW CELLS; CHILD, PRESCHOOL; FEMALE; FLOW CYTOMETRY; HUMANS; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; MYELOID PROGENITOR CELLS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; ROC CURVE; YOUNG ADULT;

EID: 79954432859     PISSN: 00029173     EISSN: 19437722     Source Type: Journal    
DOI: 10.1309/AJCP00SHTQCVUYRI     Document Type: Article

References (17)

1. Brunning RD, Germing U, Le Beau MM, et al. Myelodysplastic syndromes/neoplasms, overview. In: Swerdlow SH, Campo E, Harris NL, et al, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon, France: IARC Press; 2008: 88-93.
2. Hasle H, Niemeyer CM, Chessells JM, et al. A pediatric approach to the WHO classification of myelodysplastic and myeloproliferative diseases. Leukemia. 2003;17:277-282. (Pubitemid 36266902)
3. Head DR. Diagnosis and classification of the acute leukemias and myelodysplastic syndrome. In: Greer JP, Foerrster J, Rodgers GM, et al, eds. Wintrobe's Clinical Hematology. 12th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2009: 1808-1819.
4. Hofmann WK, de Vos S, Komor M, et al. Characterization of gene expression of CD34+ cells from normal and myelodysplastic bone marrow. Blood. 2002;100:3553-3560. (Pubitemid 35303923)
5. Pradhan A, Mijovic A, Mills K, et al. Differentially expressed genes in adult familial myelodysplastic syndromes. Leukemia. 2004;18:449-459. (Pubitemid 38425858)
6. Briggs RC, Kao WY, Dworkin LL, et al. Regulation and specificity of MNDA expression in monocytes, macrophages, and leukemia/B lymphoma cell lines. J Cell Biochem. 1994;56:559-567.
7. Johnstone RW, Trapani JA. Transcription and growth regulatory functions of the HIN-200 family of proteins. Mol Cell Biol. 1999;19:5833-5838. (Pubitemid 29399288)
8. Stehlik C, Fiorentino L, Dorfleutner A, et al. The PAAD/PYRIN-family protein ASC is a dual regulator of a conserved step in nuclear factor kappa B activation pathways. J Exp Med. 2002;196:1605-1615. (Pubitemid 36026472)
9. Briggs RC, Shults KE, Flye LA, et al. Dysregulated human myeloid nuclear differentiation antigen expression in myelodysplastic syndromes: evidence for a role in apoptosis. Cancer Res. 2006;66:4645-4651.
10. Greenberg P, Cox C, Le Beau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89:2079-2088. (Pubitemid 27132124)
11. Purvis N, Stelzer G. Multi-platform, multi-site instrumentation and reagent standardization. Cytometry. 1998;33:156-165. (Pubitemid 28447140)
12. Agresti A. Categorical Data Analysis. 2nd ed. Hoboken, NJ: Wiley; 2002.
13. Cuzick J. A Wilcoxon-type test for trend. Stat Med. 1985;4:87-90. (Pubitemid 15142530)
14. Kussick SJ, Wood BL. Using 4-color flow cytometry to identify abnormal myeloid populations. Arch Pathol Lab Med. 2003;127:1140-1147. (Pubitemid 37093263)
15. Landberg G, Roos G. Flow cytometric analysis of proliferation associated nuclear antigens using washless staining of unfixed cells. Cytometry. 1992;13:230-240.
16. Miller DT, Stelzer GT. Contributions of flow cytometry to the analysis of the myelodysplastic syndrome. Clin Lab Med. 2001;21:811-828. (Pubitemid 33127028)
17. Head DR. Revised classification of acute myeloid leukemia. Leukemia. 1996;10:1826-1831. (Pubitemid 26380031)